drugset / Trial / NCT00293059

Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding

NCT00293059

Phase 3 Completed 190 enrolled Bayer
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether the study drug is safe and effective in the treatment of dysfunctional uterine bleeding.

Timeline

Start
2005-12
Primary completion
2008-05
Completion
2008-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Dienogest Small molecule 3 mg Oral
Subject estradiol valerate Unknown 2 mg Oral

Indications